(Q37791764)

23 August 2017

title

New pharmacological strategies for the treatment of pulmonary fibrosis (English)

1 reference

23 August 2017

1 reference

1 reference

Athena Gogali

1

1 reference

23 August 2017

Athol U. Wells

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20864457

18 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20864457

18 July 2024

publication date

23 September 2010

1 reference

full work available at URL

23 August 2017

http://tar.sagepub.com/cgi/content/abstract/4/6/353

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20864457

http://journals.sagepub.com/doi/pdf/10.1177/1753465810379454

18 July 2024

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

Therapeutic advances in respiratory disease

18 July 2024

published in

1 reference

23 August 2017

volume

4

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

353-366

1 reference

Scleroderma lung disease: evolving understanding in light of newer studies

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Activation of somatostatin receptors attenuates pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

ABCA3 mutations associated with pediatric interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

High-dose acetylcysteine in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Interstitial lung disease in systemic sclerosis: a simple staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Antioxidant therapy for idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Oral cyclophosphamide for active scleroderma lung disease: a decision analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Protein C anticoagulant system in patients with interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Anticoagulant therapy for idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

The Role of PPARs in Lung Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Treatment of sarcoidosis -- from a basic science point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Idiopathic pulmonary fibrosis: new insights into pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Improving the standard of care for patients with idiopathic pulmonary fibrosis requires participation in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Idiopathic pulmonary fibrosis: current trends in management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

The treatment of lupus pernio: results of 116 treatment courses in 54 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Pirfenidone in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Mechanisms of pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Advances in the treatment of rheumatic interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: a potential role for Nrf2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Infliximab in extrapulmonary sarcoidosis: tantalising but inconclusive.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465810379454

American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis

18 July 2024

2

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice

18 July 2024

6

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression

18 July 2024

9

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling

18 July 2024

13

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis

18 July 2024

14

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention?

18 July 2024

15

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

European Review for Medical and Pharmacological Sciences

18 July 2024

18

12

105

Fiorucci, E.

2008

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy

18 July 2024

19

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis

18 July 2024

23

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial

18 July 2024

24

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

Methionine aminopeptidase-2 as a selective target of myofibroblasts in pulmonary fibrosis

18 July 2024

25

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

Anticoagulant therapy and idiopathic pulmonary fibrosis

18 July 2024

27

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice

18 July 2024

42

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil

18 July 2024

47

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

Cardiac sarcoidosis responding to monotherapy with infliximab

18 July 2024

56

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial?

18 July 2024

61

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

Decreased protein C activation is associated with abnormal collagen turnover in the intraalveolar space of patients with interstitial lung disease

18 July 2024

62

1 reference

https://api.crossref.org/works/10.1177/1753465810379454

18 July 2024

Identifiers

1 reference

23 August 2017

1 reference